BridgeBio Announces First Participant Dosed in ASCEND-ATTR, a Phase 3b/4 Study Evaluating the Long-Term Effects of Acoramidis on Disease Regression in ATTR-CM

The ASCEND-ATTR study extends prior Phase 3 ATTRibute-CM CMR substudy findings, which suggested acoramidis may improve cardiac structure and function. The article also notes evidence of amyloid regression in a subset of patients, indicating potential clinical efficacy that supports continued development and regulatory progress.